認知症の治療の進歩

抄録

The hot topic of treatment of neurocognitive disorder in 2023 is undoubtedly the approval of lecanemab and its use in patients with early Alzheimer disease (AD) in clinical settings in Japan. This is a paradigm shift in treatment of neurodegenerative diseases : we can use the disease–modifying drug for patients with AD and it is expected that efforts to resolve unmet medical needs in dementia treatment will accelerate. A number of agents are in development that target the causative proteins of neurodegenerative diseases such as tau, α–synuclein in addition to amyloid–β. In this article, we describe the results or plans of clinical studies relevant to amyloid–β, tau and α–synuclein that have been newly reported in 2023.